The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer
Abstract
BACKGROUND: Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor olaparib is combined with next-generation hormonal agent abiraterone to treat metastatic castration-resistant prostate cancer (mCRPC). METHODS: We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting. Patients were enrolled regardless of homologous recombination repair gene mutation (HRRm) status. HRRm status was determined following enrollment by tumor tissue and circulating tumor DNA tests. Patients were randomly assigned (1:1) to receive abiraterone (1000 mg once daily) plus prednisone or prednisolone with either olaparib (300 mg twice daily) or placebo. The primary end point was imaging-based progression-free survival (ibPFS) by investigator assessment. Overall survival was among the secondary end points. RESULTS: At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001) and was consistent with blinded independent central review (hazard ratio, 0.61; 95% CI, 0.49 to 0.74). At this data cutoff, overall survival data were immature (28.6% maturity; hazard ratio, 0.86; 95% CI, 0.66 to 1.12; P=0.29). The safety profile of olaparib and abiraterone was consistent with the known safety profiles of the individual drugs. The most common adverse events in the abiraterone and olaparib arm were anemia, fatigue/asthenia, and nausea. CONCLUSIONS: At primary analysis at this first data cutoff, abiraterone combined with olaparib significantly prolonged ibPFS compared with abiraterone and placebo as first-line treatment for patients with mCRPC enrolled irrespective of HRRm status. (Funded by AstraZeneca and Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; ClinicalTrials.gov number, NCT03732820.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the phase 3 PROpel trial (NCT03732820), the combination of abiraterone plus olaparib as first-line treatment resulted in improved PFS compared with abiraterone plus placebo (median: 24.8 vs 16.6 months; HR 0.66; 95% CI 0.54–0.81; p < 0.001) irrespective of HRR status [60].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [60]
In the citing paper
“Of note, patients with mCRPC who developed resistance on a prior ARPI were not represented in PROpel, MAGNITUDE, or TALAPRO-2, so the benefit of these combinations in these patients is not known [28, 60, 63].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [60]
In the citing paper
“In a post hoc exploratory analysis, the radiographic PFS (rPFS) benefit of olaparib plus abiraterone was most pronounced in the HRR-mutated (HRRm) (HR 0.50; 95% CI 0.34–0.73) and BRCAm subgroups (HR 0.23; 95% CI 0.12–0.43) [60, 61].”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [60]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citationJames, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 2,007
Self-citationScher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citationRyan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citationSurvival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Self-citation
Cited by
Sorted by citations
Items 401–430 of 430
Allaume, P., Raby, M., Nourieh, M., Lespagnol, A., Tallet, A., Péricart, S., Tantot, J., Lindner, V., Decaussin‐Petrucci, M., Callens, C., et al. (2026) · The French Journal of Urology · doi:10.1016/j.fjurol.2026.103148
Abahssain, H., Sabri, O., Lemaire, A., & Souadka, A. (2026) · Cancers · doi:10.3390/cancers18121949
Dai, T., Xu, Z., Wang, H., Han, W., Zhang, D., Tang, K., Wang, X., Huang, J., He, C., Zhou, X., et al. (2026) · BMC Cancer · doi:10.1186/s12885-026-16182-0
Compérat, É., Amsberg, G. V., Corrigan, L., Finn, S. P., Kristiansen, G., Minucci, A., Olmos, D., & Roubaud, G. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1874947
Miedziarek, C., Caputa, P., Bochyński, H., Zaborowski, M. P., & Nowak‐Markwitz, E. (2026) · Cancers · doi:10.3390/cancers18132157
Prostate Cancer Development, Progression, and Therapy
Jin, X., Xiao, Z., Ding, Z., Li, W., Zeng, R., Shuai, Y., Ci, W., Xia, D., Zhang, X., & Huang, H. (2026) · MedComm – Oncology · doi:10.1002/mog2.70082
Okumura, G., Yoshida, S., Hirose, K., Yajima, S., Chen, W., Hirakawa, A., Fujiwara, M., Fukushima, H., Arita, Y., Tanaka, H., et al. (2026) · Asian journal of urology · doi:10.1016/j.ajur.2026.02.002
Genitourinary Cancer: Recent Advances in Diagnosis and Treatment
Zhang, J., & Zimmerman, J. (2026) · Springer eBooks · doi:10.1007/978-3-032-19175-5_20
Rodríguez-Olivares, J. L., Pineda, M. M., Beas-Lozano, E. L., Seidman-Sorsby, A., Remolina-Bonilla, Y. A., Gamboa‐Domínguez, A., Weitzel, J. N., Barata, P., Chavarri-Guerra, Y., & Bourlon, M. T. (2026) · ONCOLOGY · doi:10.46883/2026.25921234
Žist, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-30050-9.00033-3
Garofoli, M., Natalicchio, M. I., Bruno, G., Rosano, A., Maiorano, B. A., Rossetti, S., Scagliarini, S., Incorvaia, L., Formisano, L., Toma, I., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-05086-2
Taxane therapy in mCRPC: current positioning and emerging strategies to overcome resistance
Wang, L., Tang, Y., Liu, M., Zhou, H., Zeng, H., & Tang, B. (2026) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2026.2713042
Choudhury, A. D., Zhong, C., Xie, W., Kochupurakkal, B. S., Wu, P. I.-F., Riaz, I. B., Liu, R., Yang, D. D., Folefac, E., Lee, D., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-26-0488
Nukaya, T., Naiki, T., Watanabe, H., Nakane, K., Inamoto, T., Yasui, T., Koie, T., & Takahara, K. (2026) · International Journal of Urology · doi:10.1111/iju.70626
Dai, H., Jiang, L., Gu, Q., Yao, C., Yu, D., Chao, A., Xie, J., Xu, H., Zhu, N., Zhao, B., et al. (2026) · medRxiv · doi:10.64898/2026.08.26.26361314
Therapiemanagement des mCRPC im Jahr 2026
Wielander, D. (2026) · Uro-News · doi:10.1007/s00092-026-7048-z
Molecular testing for prostate cancer patients in Greece
Liontos, M., Kunadis, E., Παπανώτα, Α.-Μ., Svarna, A., Aravantinou-Fatorou, K., Michas, A., Dedes, N. G., Andrikopoulou, Α., Kaparelou, M., & Dimopoulos, M. A. (2026) · Hellenic Urology · doi:10.23736/s2241-9136.25.00107-0
Liquid biopsy: a new window on the BRCA genes
Incorvaia, L., Gristina, V., Pepe, F., Russo, T. D. B., Santoni, M., Mujacic, C., Curigliano, G., Malapelle, U., Capoluongo, E. D., & Russo, A. D. (2026) · ESMO Open · doi:10.1016/j.esmoop.2026.108349
Chen, X., Huang, Q., Li, R., Cao, L.-Q., Gong, K., Wang, N., Ashby, C. R., Gu, J., & Chen, Z. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109126
Sereti, E., Axelsson, S. E., Törnell, J., Rehnmark, S., Högberg, M., & Bjartell, A. S. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04946-1
Jhan, J., Geng, J., Ke, H., Huang, S., & Li, J. (2026) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.70292
Modern trends in the use of abiraterone. A review of clinical and experimental research
Uryupina, A. A., Petko, V. S., Крюк, Т. В., Gyulmamedov, D. N., Iordanidi, T. A., Додохова, М. А., & Котиева, И. М. (2026) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2026-25-4-135-144
Kjer, M. F., Poulsen, M. H., Kjær‐Frifeldt, S., Holt, M. I., Vilstrup, M. H., & Zedan, A. H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198453
Hereditary cancer syndromes as a model for precision oncology: the paradigms of HRD and MSI
Pepa, C. D., Mignano, A., Zitiello, M., Pesce, L., Caliendo, G., Stilo, M., & VIETRI, M. T. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101456
Mehra, N., Clarke, N. W., Armstrong, A. J., Oya, M., Shore, N. D., Procopio, G., Guedes, J. D., Arslan, Ç., Brown, E., Joung, J. Y., et al. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.08.014
Self-citationHabano, E., Sato, Y., Ogawa, M., Watanabe, K., Akiyama, N., Chang, H., Shijiki, E., Nagai, S., Kunita, A., Ueki, A., et al. (2026) · International Journal of Clinical Oncology · doi:10.1007/s10147-026-03209-6
The role of PARP inhibition and HRR alterations in mHSPC: current evidence and future perspectives
Crippa, N., Montelatici, G., Claps, M., Guadalupi, V., Gusmaroli, E., Mascaro, F., Nuzzo, A., Rametta, A., Sciortino, C., Rota, S., et al. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359261449096
Self-citationIncorvaia, L., Mollica, V., Fiala, O., Fujita, K., Ürün, Y., Melichar, B., Molina‐Cerrillo, J., Alonso‐Gordoa, T., Basso, U., Bourlon, M. T., et al. (2026) · The Prostate · doi:10.1002/pros.70269
Self-citationZacchi, F., Castro, E., Imbach, K., Rodríguez‐Vida, A., Simonetti, S., Mellado, B., Mir, G., Aguilar, D., Castellano, D., Climent, M. A., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04671-5
Metadata
- Authors
- Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J. Y., Sugimoto, M., Virizuela, J. A., Emmenegger, U., Navratil, J., Buchschacher, G. L., Poehlein, C., Harrington, E. A., Desai, C., Kang, J., & Saad, F.
- Affiliations
- University of Manchester (GB)
- Duke University (US)
- Centre Hospitalier Universitaire de Besançon (FR)
- Keio University (JP)
- Carolina Urologic Research Center (US)
- Centro de Investigaciones Clinicas Viña del Mar, Valparaíso, Chile
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Hospital Nossa Senhora da Conceição (BR)
- Hospital de Base (BR)
- Izmir Economy University Medical Park Hospital, Karsiyaka, Turkey
- Radboud University Medical Center (NL)
- Ashford Cancer Centre Research, Adelaide, South Australia
- University Hospital Southampton NHS Foundation Trust (GB)
- Centre Hospitalier de Cornouaille (FR)
- National Cancer Center (KR)
- Kagawa University Hospital (JP)
- Hospital Universitario Virgen Macarena (ES)
- Sunnybrook Research Institute (CA)
- Masaryk Memorial Cancer Institute, Brno, Czech Republic
- Kaiser Permanente (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Centre Hospitalier de l’Universite de Montreal, Montreal
- ORCID
- Venue
- NEJM Evidence
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-23
- Volume
- 1
- Issue
- 9
- Pages
- EVIDoa2200043-EVIDoa2200043
- ISSN
- 2766-5526 (ISSN-L)
- OpenAlex
- W4281770555
- Cited by
- 426
- References
- 27
- Citations by year
- 2026: 77 · 2025: 108 · 2024: 111 · 2023: 110 · 2022: 20
- FWCI
- 56.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- NEJM Evidence (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- abiraterone, olaparib, metastatic castration-resistant prostate cancer, PARP inhibitors, first-line therapy, homologous recombination deficiency, progression-free survival, overall survival, combination therapy, PARP inhibitor resistance, circulating tumor DNA, anemia, fatigue, nausea, hormone therapy
- MeSH terms
- Androstenes, Antineoplastic Combined Chemotherapy Protocols, Humans, Male, Phthalazines, Piperazines, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
